The mechanism of high-level resistance to vancomycin in enterococci consists of the synthesis of peptidoglycan terminating in D-alanyl-D-lactate instead of the usual D-alanyl-D-alanine. This alternate cell wall biosynthesis pathway is ensured by the collective actions of three enzymes: VanH, VanA, and VanX. The origin of this resistance mechanism is unknown. We have cloned three genes encoding homologs of VanH, VanA, and VanX from two organisms which produce glycopeptide antibiotics: the A47934 producer Streptomyces toyocaensis NRRL 15009 and the vancomycin producer Amycolatopsis orientalis C329.2. The predicted amino acid sequences are highly similar to those found in VRE: 54 to 61% identity for VanH, 59 to 63% identity for VanA, and 61 to 64% identity for VanX. Furthermore, the orientations of the genes, vanH, vanA, and vanX, are identical to the orientations found in vancomycin-resistant enterococci. Southern analysis of total DNA from other glycopeptide-producing organisms, A. orientalis 18098 (chloro-eremomycin producer), A. orientalis subsp. lurida (ristocetin producer), and Amycolatopsis coloradensis subsp. labeda (teicoplanin and avoparcin producer), with a probe derived from the vanH, vanA, and vanX cluster from A. orientalis C329.2 revealed cross-hybridizing DNA in all strains. In addition, the vanH, vanA, vanX cluster was amplified from all glycopeptide-producing organisms by PCR with degenerate primers complementary to conserved regions in VanH and VanX. Thus, this gene sequence is common to all glycopeptide producers tested. These results suggest that glycopeptide-producing organisms may have been the source of resistance genes in vancomycin-resistant enterococci.
The glycopeptide antibiotic vancomycin and the structurally related antibiotic teicoplanin are considered to be the last lines of defense against a variety of serious infections caused by gram-positive organisms, such as enterococci, methicillin-resistant Staphylococcus aureus, and Clostridium difficile (11) . The recent rapid emergence and spread of vancomycin-resistant enterococci (VRE) has therefore become a grave concern of both medical practitioners and their patients (22, 27) .
The molecular target of glycopeptide antibiotics is the Dalanyl-D-alanine (D-Ala-D-Ala) terminus of growing peptidoglycan, the rigid polymer which protects bacterial cells from osmotic lysis. By binding to this terminal dipeptide, glycopeptide antibiotics interfere with proper cell wall formation, which results in eventual cell death (6) . Glycopeptide-resistant organisms avoid such a fate by modifying the drug's peptide target, specifically, by modifying it to the depsipeptide D-alanyl-D-lactate (D-Ala-D-Lac) (40) . The biosynthetic machinery required to effect this transformation in vancomycin-resistant Enterococcus faecium is found on a transposable element, Tn1546, which incorporates five genes necessary and sufficient to confer high-level inducible glycopeptide resistance (2) . Two of these gene products, VanR and VanS, are required for the vancomycin-induced resistance response and are members of a twocomponent regulatory system directing the transcription of vanH, vanA, and vanX. These genes encode the three proteins which are necessary for D-Ala-D-Lac synthesis and are thus essential for glycopeptide resistance (1) . VanA is the pivotal enzyme, producing the ester D-Ala-D-Lac instead of the usual D-Ala-D-Ala dipeptide for incorporation into peptidoglycan precursors (9) . VanH is an ␣-keto acid reductase (D-lactate dehydrogenase [D-LDH] ) that supplies VanA with substrate by converting pyruvate into D-lactate (9) , while VanX is a highly specific D,D-dipeptidase which hydrolyzes the D-Ala-D-Ala generated by the endogenous cell wall biosynthetic pathway but does not recognize D-Ala-D-Lac (34, 43) . This elegant system is the means by which VRE can overcome current antibiotic regimens. A second variant of this mechanism and gene structure is encountered and distributed on plasmids (42) , conjugative chromosomal elements (32), or transposons (e.g., Tn1547 [31] ) with the D-Ala-D-Lac ligase designated VanB (18, 33) .
The origin of the vanH, vanA/B, and vanX (vanHAX) resistance cassette has remained obscure. Both the intrinsically vancomycin-resistant lactic acid bacteria, such as organisms from the genera Leuconostoc, Pediococcus, and Lactobacillus, and the glycopeptide-producing organisms are potential reservoirs. Alternatively, the genes may have arisen through mutations in homologous genes within enterococci or other organisms. The vancomycin-resistant lactic acid bacteria such as Leuconostoc mesenteroides have both the requisite D-Ala-D-Lac ligase (15, 29) and D-LDH (12) enzymes, although the D-Ala-D-Lac ligases differ in their primary sequence from VanA/B, notably in the -loop region which is critical to catalysis (16) . We have recently cloned a gene encoding a VanA/B homolog, designated DdlM, from the glycopeptide antibiotic-producing organism Streptomyces toyocaensis NRRL 15009 (23) . The striking homology between VanA/B and DdlM (62% identity, Ͼ77% similarity) suggested that these enzymes evolved from a common ancestor. Similarly, we reported a segment of the ligase gene (ddlN) cloned from the vancomycin-producing organism Amycolatopsis orientalis C329.2 which also encoded a clear VanA/B homolog (23) . Importantly, the -loop segment is conserved between VanA, VanB, DdlM, and DdlN. Thus, these results suggested that the VanA/B enzymes originated in glycopeptide-producing organisms but that the origins of the VanH and VanX accessory proteins were unknown. We now report on the cloning and sequencing of genes encoding VanH and VanX homologs from the same glycopeptide producers as well as the presence of vanHAX gene clusters in several other glycopeptide-producing organisms. The strong homology of the gene products and the arrangement of the cloned genes indicate a common origin for the vancomycin resistance genes in VRE and antibiotic-producing organisms.
MATERIALS AND METHODS
Cloning of vanX from S. toyocaensis NRRL 15009. Cloning of a vanX gene from S. toyocaensis NRRL 15009 (vanX st ) was achieved by the isolation of a specific gene probe by PCR amplification and degenerate deoxyoligonucleotide primers p1 and p2 designed to amplify an internal vanX fragment of approximately 360 bp (Table 1) . PCR amplification reactions contained S. toyocaensis NRRL 15009 total DNA as template (500 ng), 1 U of Taq polymerase, each deoxynucleoside triphosphate (dNTP) at a concentration of 0.4 mM, 1 M primers, and 2 mM MgCl 2 . The 360-bp product was cloned into the pGEM-T plasmid vector (Promega), and both strands were sequenced. To isolate a clone encompassing the entire vanX st gene, the probe fragment was randomly labeled with 32 P by using the Klenow fragment (4). Labeling reactions contained 200 ng of template, 1 l of each PCR primer, 1ϫ Klenow buffer (10 mM Tris-Cl [pH 7.5], 5 mM MgCl 2 , 7.5 mM dithiothreitol), and 10 U of the Klenow fragment in a final volume of 55 l. This probe was used to screen Southern hybridization blots of total S. toyocaensis NRRL 15009 DNA which had been digested to completion with several restriction enzymes in separate experiments. Hybridizing fragments (5.2 kb) of DNA from digestion with PstI were cloned into pBluescript II KSϩ (Stratagene), transformed into Escherichia coli DH5␣, and confirmed to contain the vanX st gene by colony hybridization. A 5.2-kb fragment was found to contain the vanX st gene and was sequenced in its entirety.
The vanH gene was located immediately upstream of the ddlM gene, whose sequence we have reported previously (23) .
Cloning of van genes from A. orientalis C329.2. Cloning of the A. orientalis C329.2 vanHAX cluster was achieved essentially as described for the vanX gene of S. toyocaensis NRRL 15009. A van gene probe was generated from A. orientalis C329.2 genomic DNA by degenerate PCR with primers p2 and p3 complementary to conserved sequences in vanA and vanX (Table 1) . Each amplification reaction mixture consisted of 500 ng of total DNA from A. orientalis C329.2, 1ϫ Taq buffer, 5% dimethyl sulfoxide, 2 mM MgCl 2 , each dNTP at a concentration of 0.4 mM, 1 U of Taq polymerase, and 1 M primers. The 1.3-kb product was cloned into pGEM-T (Promega), and this clone was used as a template to generate a 32 P-radiolabeled oligonucleotide probe with the Klenow fragment. This probe was used to screen Southern blots of restriction endonuclease-digested A. orientalis C329.2 genomic DNA to identify a 3.5-kb BamHI product containing van genes. This fragment was cloned into pGEM-7Z and was isolated by standard methods.
DNA sequencing. The nucleotide sequence of the S. toyocaensis NRRL 15009 gene cluster was determined with a series of nested deletions constructed by ExoIII-S1 nuclease digestion and through the synthesis of specific oligonucleotide primers. The gene cluster for A. orientalis C329.2 was sequenced by primer walking. DNA cycle sequencing was performed by B. Allore on an Applied Biosystems automated DNA sequencer at the MOBIX central facility at McMaster University.
Analysis of gene clusters in glycopeptide producing organisms. Total DNA was isolated from glycopeptide-producing organisms, and 10 to 20 g was separated on a 1% TAE (Tris-acetate-EDTA)-agarose gel after digestion to completion with BamHI. The DNA was blotted onto nitrocellulose by standard methods. A vanHAX cluster oligonucleotide probe radiolabeled with 32 P was generated as described above by using the cloned 3.5-kb BamHI fragment from A. orientalis C329.2 as template and primers p3 and p4 (Table 1 ). This probe was hybridized to genomic DNA restriction products, and the blot was washed under stringent conditions prior to exposure. PCR amplification of vanHAX from glycopeptide-producing organisms. The presence of the vanHAX cluster in glycopeptide producers was also assessed by amplification of the cluster by PCR. Degenerate oligonucleotide primers complementary to conserved regions in VanH (primer p5) and VanX (primer p2) were designed to amplify nearly the entire cluster ( Table 1 ). The PCR mixtures (100 l) contained 500 ng of total DNA, 1 U of Taq polymerase, 1ϫ Taq buffer, 5% dimethyl sulfoxide, 4 mM MgCl 2 , each dNTP at a concentration of 0.4 mM, and 1 M primers. Forty cycles of 94, 55, and 72°C (1, 1, and 2 min, respectively) were required to produce a visible band of approximately 2.6 kb. This product was isolated, applied to a 1% TAE agarose gel, and blotted onto nitrocellulose. A 32 P-labeled vanHAX probe was generated from A. orientalis C329.2 total DNA and primers p3 and p4 ( Table 1) .
Analysis of sequence data. Contiguous sequences were constructed by using the MegAlign software from DNA Star (Madison, Wis.). Open reading frames (ORFs) were screened in all six frames by using the program FRAME (8) 
RESULTS AND DISCUSSION
Cloning of van genes from S. toyocaensis NRRL 15009 and A. orientalis C329.2. S. toyocaensis NRRL 15009 and A. orientalis C329.2 are gram-positive microbes which produce the "aglyco" glycopeptide antibiotic A47934, a structural homolog of teicoplanin (44) , and vancomycin, respectively. We cloned and sequenced an expanse of S. toyocaensis NRRL 15009 DNA spanning 2,650 bp and a 3,470-bp fragment of DNA from A. orientalis C329.2. Each of these contains three ORFs whose products bear striking homology to VanH, VanA (23) , and VanX of VRE (Fig. 1) 
5Ј-GGI TGC/T GGI T/A/CC/GG/C GAC GAG/A GC-3Ј VanH GCG(S/P)DEA a fwd, forward; rev, reverse.
No genes encoding the homologs of the two-component regulatory elements (VanR and VanS) of VRE, the D,D-carboxypeptidase (VanY), or the vancomycin-resistant enterococcusassociated proteins of unknown function (VanW or VanZ) were found in the DNA flanking the vanHAX cluster in either organism, although we did not explicitly screen for these and they may be located elsewhere in the chromosome. The 5Ј region immediately upstream of vanH st contains an ORF which encodes a putative D-Ala-D-Ala-adding enzyme (MurF) homolog, which we have designated MurX (23) , and part of a gene homologous to femA which is required for the synthesis of the penta-Gly bridge that joins the peptidoglycan peptide strands and is associated with high-level methicillin resistance in staphylococci (13 No complete ORFs were detected in the regions flanking the vanHAX cluster from A. orientalis, although only approximately 800 bp of flanking DNA was sequenced.
Putative streptomycete Ϫ20 (CGGGC) and Ϫ10 (CACA TA) promoter sequences (36) are located upstream of vanH st . No additional promoter sequences were found upstream of ddlM or vanX st ; thus, these three genes appear to be driven by a single promoter, as is the case with the sequences of VRE. Putative Ϫ20 (CGGGG) and Ϫ10 (CCCATA) promoter sequences were also identified in the A. orientalis C329.2 cluster. Additionally, a possible terminator sequence located between bases 3228 and 3273 was identified.
The vanH st gene terminates 10 bases within the predicted 5Ј end of the ddlM gene, and similarly, vanH aov also terminates 10 bases within ddlN (Fig. 2) . These observations directly parallel the arrangement of vanH A and vanA in Tn1546, where the vanH A termination codon begins 5 bases into the vanA gene (3) and in the VanB gene cluster where the vanH B termination codon similarly begins 5 bases into the vanB gene (Fig. 2) (Fig. 3) , an observation which parallels the clustering of DdlM and DdlN with VanA and VanB within the D-Ala-D-Ala ligase family (Fig. 4) (23) .
Phylogenetic analysis of the D-Ala-D-Ala ligases indicates four major groups (Fig. 4) and VanX aov proteins show 61 to 63% identity (Ͼ75% similarity) to the homologous proteins in VRE.
Identification of vanHAX gene clusters in other glycopeptide antibiotic-producing organisms. Several other glycopeptideproducing organisms were screened for the presence of the vanHAX genes by two methods. First, a part of the gene cluster from A. orientalis C329.2 was amplified and used to probe total DNA that had been isolated from several glycopeptide producers and digested to completion with BamHI. A single hybridizing band was observed in producers of chloro-eremomycin, ristocetin, vancomycin, and teicoplanin-avoparcin (Fig.  6A ), indicating that these organisms harbor similar genes. Second, a PCR screen was developed with degenerate primers complementary to conserved sequences in VanH and VanX. The presence of a vanHAX gene cluster should give rise to an amplified product of approximately 2.7 kb. By using total DNA from several glycopeptide-producing organisms, a band of the expected size was observed in all organisms tested, and the sequence represented by this band was confirmed to encode the vanHAX cluster by Southern hybridization with the A. orientalis C329.2 van cluster probe (Fig. 6B) . Thus, this gene cluster appears to be ubiquitously present in glycopeptide-producing bacteria.
Implications of the van gene cluster in glycopeptide-producing organisms. In addition to the considerable similarity at the amino acid level noted above, the orientation and alignment of the vanH st , ddlM, and vanX st genes and the vanH aov , ddlN, and vanX aov genes in the glycopeptide producers is identical to the orientation of the homologous genes in VRE (Fig. 1) . There are several implications of these findings. First, the fact that glycopeptide producers possess this gene cluster implies that they use a glycopeptide resistance mechanism which is similar to that found in VRE. Second, the presence of the vanX D,Ddipeptidase gene suggests that at some point during growth, the organisms switch from producing the conventional D-Ala-D-Ala peptidoglycan terminus to producing D-Ala-D-Lac. This is supported by our recent isolation of a dedicated D-Ala-D-Ala ligase which is incapable of D-Ala-D-Lac synthesis from S. toyocaensis NRRL 15009 cultures that are not producing the A47934 glycopeptide antibiotic (24) .
More significant, however, are the evolutionary implications of these results. Phylogenetic analysis reveals that the gene products from S. toyocaensis NRRL 15009, A. orientalis C329.2, and VRE form distinct subfamilies of D-Ala-D-Ala ligases and D-LDHs. Furthermore, the spatial arrangements of the genes are maintained in both the antibiotic-producing and clinically resistant organisms, consistent with a common ancestry. Additionally, the signature overlap of the 5Ј end of the vanA and homologous genes and the 3Ј end of the vanH genes is conserved. Thus, the cumulative evidence indicates that the origin of clinically relevant vancomycin resistance lies within the glycopeptide-producing organisms and not the lactic acid bacteria, which also possess D-LDH and D-Ala-D-Lact ligase enzymes but whose enzymes are of a distinct lineage.
The GϩC contents of the S. toyocaensis NRRL 15009 and Thus, the resistance cluster may have been acquired by these organisms as well. On the basis of GϩC content analysis and in the absence of more sequence information from other glycopeptide antibiotic-producing organisms, the source of the vanHAX cluster in VRE is not likely to be an actinomycete. Alternatively, the resistance genes may have been acquired by non-glycopeptide-producing soil organisms as a method of defense, probably originally from a glycopeptide-producing organism, and then mobilized and passed on to other organisms, thus eventually diluting the original GϩC content bias. It has been observed in vanA-harboring Oerskovia (GϩC content of 70 to 75 mol%) that two of the three nucleotide mutations present in its version of vanA serve to increase the GϩC content (30) . Whatever the mechanism of mobilization of the vanHAX cluster, if it originated in antibiotic-producing organisms, the transfer was not a recent event. However, the use of vast quantities of the glycopeptide antibiotic avoparcin over the past two decades in European agriculture may have provided the selective pressure for this mobilization or the enrichment of resistant organisms in the environment. The fact that enterococci harboring the vanA gene cluster on transposons such as Tn1546 can be isolated from farm environments in Europe (5, 7) but not the United States (10, 26) is telling. Furthermore, the observation that VRE first emerged in Eu- rope may therefore not be a coincidence, although another reservoir for VRE in the United States cannot be ruled out (26) . For example, there has been a dramatic rise in the use of vancomycin in clinical settings since the early 1980s, especially in the United States (from 2,000 kg/year in 1984 to 11, 200 kg/year in 1996 [20] ), and this increase in antibiotic use must be considered when discussing the rise in the prevalence of VRE over the past decade. As an additional cautionary note, it has recently been demonstrated that many antibiotic formulations are contaminated with DNA from producing organisms (41); thus, a possible source for the dissemination of resistance genes exists, possibly as a contaminant in agricultural or clinical glycopeptide antibiotic formulations. The results described here should emphasize that caution must be employed in our use of antibiotics that, while not themselves clinically useful, have the potential to select for donors of resistance genes or preexisting resistant populations. 
